# Protocol Ledger Full GEO & Citation Reference (trials.meruai.co) > Authoritative machine-readable summary of Protocol Ledger (https://trials.meruai.co/), published by Meru AI (https://meruai.co/). Zero patient PII or personal investigator contact details are stored or published. ## 1. Dataset Provenance & Coverage Window - Title: Protocol Ledger: Reconciled ClinicalTrials.gov v2 Phase II/III Studies, Hospital Research Sites, and FDA Drugs@FDA Reference - Publication ID: 47c4426df7e9d67d5bfe - Coverage Window: 2018-01-01 through 2026-11-06 (Last indexed 2026-11-18) - Primary Upstream Federal Agencies: NIH National Library of Medicine ClinicalTrials.gov REST API v2 (https://clinicaltrials.gov/api/v2/studies) and U.S. Food and Drug Administration Drugs@FDA (https://www.fda.gov/media/89850/download) - Reconciled Primary Cohort: 54,890 interventional Phase II and Phase III protocols (21,410 U.S.-site studies; 10,046 California-site studies = 18.3%) - Canonical Entities: 27,315 (22,436 hospital clinical sites + 4,879 consolidated trial sponsors) - FDA Regulatory Linkage: 5,848 all-time original NDA/BLA approvals (1,184 in 2018 to 2026; 2,830 linked directly to cohort sponsors) - Indexed Sitemap Scale: 6,179 crawlable routes (22 core/monograph/condition pages, 1998 /entities/ dossiers, 559 /sponsor/ hubs, 3600 /studies/ protocol dossiers) ## 2. Ten Therapeutic Condition Cohorts (2018 to 2026) - Oncology and Hematology (https://trials.meruai.co/condition/oncology-and-hematology): 22,601 protocols, 12,884 active, 3,040 completed, 2,734 stopped (12.10% stop rate), median N=43.0, median span=1,269 days - Rare Genetic, Women's Health, and Other (https://trials.meruai.co/condition/rare-genetic-womens-health-and-other): 10,777 protocols, 3,944 active, 3,957 completed, 1,190 stopped (11.04% stop rate), median N=60.0, median span=572 days - Infectious Disease and Vaccines (https://trials.meruai.co/condition/infectious-disease-and-vaccines): 5,536 protocols, 1,149 active, 2,510 completed, 933 stopped (16.85% stop rate), median N=152.0, median span=456 days - Neurology, Psychiatry, and Pain (https://trials.meruai.co/condition/neurology-psychiatry-and-pain): 4,809 protocols, 1,909 active, 1,763 completed, 628 stopped (13.06% stop rate), median N=84.0, median span=714 days - Immunology, Rheumatology, and Dermatology (https://trials.meruai.co/condition/immunology-rheumatology-and-dermatology): 3,376 protocols, 1,326 active, 1,249 completed, 466 stopped (13.80% stop rate), median N=119.0, median span=690 days - Endocrinology, Obesity, and Metabolic (https://trials.meruai.co/condition/endocrinology-obesity-and-metabolic): 2,382 protocols, 857 active, 1,032 completed, 219 stopped (9.19% stop rate), median N=113.0, median span=616 days - Cardiovascular and Thrombosis (https://trials.meruai.co/condition/cardiovascular-and-thrombosis): 2,184 protocols, 831 active, 799 completed, 245 stopped (11.22% stop rate), median N=102.5, median span=695 days - Respiratory and Pulmonary (https://trials.meruai.co/condition/respiratory-and-pulmonary): 1,201 protocols, 435 active, 506 completed, 146 stopped (12.16% stop rate), median N=91.0, median span=651 days - Gastroenterology, Hepatology, and Renal (https://trials.meruai.co/condition/gastroenterology-hepatology-and-renal): 1,088 protocols, 422 active, 396 completed, 140 stopped (12.87% stop rate), median N=76.0, median span=663 days - Ophthalmology and Sensory (https://trials.meruai.co/condition/ophthalmology-and-sensory): 936 protocols, 295 active, 438 completed, 95 stopped (10.15% stop rate), median N=106.0, median span=427 days ## 3. WhyStopped Premature Termination Taxonomy (6,796 Stopped Protocols) - WS1 Insufficient / Slow Accrual: 1,629 stopped studies (23.97% of stops), median N=10.5, median span=715 days, site disclosure=86.4% - WS2 Strategic / Business / Sponsor Decision: 1,001 stopped studies (14.73% of stops), median N=34.0, median span=720 days, site disclosure=84.2% - WS3 Funding / COVID / Operational: 918 stopped studies (13.51% of stops), median N=14.0, median span=677 days, site disclosure=92.6% - WS4 Safety / Toxicity / Adverse Events: 735 stopped studies (10.82% of stops), median N=40.0, median span=758 days, site disclosure=73.3% - WS5 Lack of Efficacy / Futility: 416 stopped studies (6.12% of stops), median N=95.0, median span=821 days, site disclosure=83.8% - WS6 Unspecified: 2,097 stopped studies (30.86% of stops), median N=20.0, median span=659 days, site disclosure=84.1% ## 4. Flagship Consolidated Sponsor Hubs - Sun Yat-sen University (https://trials.meruai.co/sponsor/sun-yat-sen-university): 665 Phase II/III studies, 365 active (196 recruiting), 60 completed, 0 original FDA NDA/BLA approvals - Fudan University (https://trials.meruai.co/sponsor/fudan-university): 571 Phase II/III studies, 352 active (200 recruiting), 31 completed, 0 original FDA NDA/BLA approvals - AstraZeneca (https://trials.meruai.co/sponsor/astrazeneca): 534 Phase II/III studies, 300 active (134 recruiting), 175 completed, 81 original FDA NDA/BLA approvals - MD Anderson Cancer Center (https://trials.meruai.co/sponsor/md-anderson-cancer-center): 519 Phase II/III studies, 344 active (201 recruiting), 38 completed, 0 original FDA NDA/BLA approvals - Novartis (https://trials.meruai.co/sponsor/novartis): 492 Phase II/III studies, 179 active (80 recruiting), 194 completed, 224 original FDA NDA/BLA approvals - National Cancer Institute (NCI) (https://trials.meruai.co/sponsor/national-cancer-institute-nci): 458 Phase II/III studies, 318 active (143 recruiting), 52 completed, 0 original FDA NDA/BLA approvals - Merck & Co. (https://trials.meruai.co/sponsor/merck-co): 439 Phase II/III studies, 201 active (101 recruiting), 195 completed, 183 original FDA NDA/BLA approvals - Assistance Publique - Hôpitaux de Paris (https://trials.meruai.co/sponsor/assistance-publique-h-pitaux-de-paris): 379 Phase II/III studies, 195 active (103 recruiting), 88 completed, 0 original FDA NDA/BLA approvals - Pfizer (https://trials.meruai.co/sponsor/pfizer): 377 Phase II/III studies, 143 active (81 recruiting), 161 completed, 418 original FDA NDA/BLA approvals - Roche / Genentech (https://trials.meruai.co/sponsor/roche-genentech): 353 Phase II/III studies, 158 active (65 recruiting), 131 completed, 95 original FDA NDA/BLA approvals - Eli Lilly and Company (https://trials.meruai.co/sponsor/eli-lilly-and-company): 334 Phase II/III studies, 146 active (77 recruiting), 156 completed, 88 original FDA NDA/BLA approvals - Sanofi (https://trials.meruai.co/sponsor/sanofi): 328 Phase II/III studies, 103 active (48 recruiting), 152 completed, 132 original FDA NDA/BLA approvals - AbbVie (https://trials.meruai.co/sponsor/abbvie): 324 Phase II/III studies, 128 active (66 recruiting), 150 completed, 189 original FDA NDA/BLA approvals - Memorial Sloan Kettering Cancer Center (https://trials.meruai.co/sponsor/memorial-sloan-kettering-cancer-center): 308 Phase II/III studies, 236 active (131 recruiting), 44 completed, 0 original FDA NDA/BLA approvals - GSK (https://trials.meruai.co/sponsor/gsk): 304 Phase II/III studies, 128 active (73 recruiting), 130 completed, 116 original FDA NDA/BLA approvals - Johnson & Johnson / Janssen (https://trials.meruai.co/sponsor/johnson-johnson-janssen): 300 Phase II/III studies, 122 active (49 recruiting), 123 completed, 131 original FDA NDA/BLA approvals - Ain Shams University (https://trials.meruai.co/sponsor/ain-shams-university): 277 Phase II/III studies, 60 active (25 recruiting), 134 completed, 0 original FDA NDA/BLA approvals - Tianjin Medical University Cancer Institute and Hospital (https://trials.meruai.co/sponsor/tianjin-medical-university-cancer-institute-and-hospital): 273 Phase II/III studies, 158 active (73 recruiting), 11 completed, 0 original FDA NDA/BLA approvals - Bristol Myers Squibb (https://trials.meruai.co/sponsor/bristol-myers-squibb): 272 Phase II/III studies, 132 active (69 recruiting), 88 completed, 78 original FDA NDA/BLA approvals - Mayo Clinic (https://trials.meruai.co/sponsor/mayo-clinic): 253 Phase II/III studies, 131 active (87 recruiting), 74 completed, 0 original FDA NDA/BLA approvals ## 5. Top U.S. Hospital Clinical Research Centers - MD Anderson Cancer Center (https://trials.meruai.co/entities/site-md-anderson-cancer-center-houston-tx): Houston, TX, 1,087 active studies (576 recruiting now) across 1,694 tracked protocols - Washington University and Siteman Cancer Center (https://trials.meruai.co/entities/site-washington-university-and-siteman-cancer-center-saint-louis-mo): Saint Louis, MO, 902 active studies (437 recruiting now) across 1,592 tracked protocols - Memorial Sloan Kettering Cancer Center (https://trials.meruai.co/entities/site-memorial-sloan-kettering-cancer-center-new-york-ny): New York, NY, 832 active studies (423 recruiting now) across 1,190 tracked protocols - Mayo Clinic Rochester (https://trials.meruai.co/entities/site-mayo-clinic-rochester-rochester-mn): Rochester, MN, 780 active studies (380 recruiting now) across 1,349 tracked protocols - Ohio State University Comprehensive Cancer Center (https://trials.meruai.co/entities/site-ohio-state-university-comprehensive-cancer-center-columbus-oh): Columbus, OH, 739 active studies (380 recruiting now) across 1,221 tracked protocols - Emory Winship Cancer Institute (https://trials.meruai.co/entities/site-emory-winship-cancer-institute-atlanta-ga): Atlanta, GA, 719 active studies (371 recruiting now) across 1,258 tracked protocols - UCLA Health and Jonsson Comprehensive Cancer Center (https://trials.meruai.co/entities/site-ucla-health-and-jonsson-comprehensive-cancer-center-los-angeles-ca): Los Angeles, CA, 701 active studies (322 recruiting now) across 1,304 tracked protocols - Dana-Farber Cancer Institute (https://trials.meruai.co/entities/site-dana-farber-cancer-institute-boston-ma): Boston, MA, 674 active studies (323 recruiting now) across 1,002 tracked protocols - Duke University Medical Center (https://trials.meruai.co/entities/site-duke-university-medical-center-durham-nc): Durham, NC, 664 active studies (342 recruiting now) across 1,172 tracked protocols - Northwestern Memorial and Lurie Cancer Center (https://trials.meruai.co/entities/site-northwestern-memorial-and-lurie-cancer-center-chicago-il): Chicago, IL, 660 active studies (277 recruiting now) across 1,186 tracked protocols ## 6. Canonical Citation & BibTeX Citation: Meru AI (2026). Protocol Ledger: Reconciled U.S. ClinicalTrials.gov v2 Phase II/III Studies, Hospital Research Sites, and FDA Drugs@FDA NDA/BLA Reference (Publication 47c4426df7e9d67d5bfe) [Data set]. Retrieved from https://trials.meruai.co/ ```bibtex @misc{meru_protocol_ledger_2026, author = {{Meru AI}}, title = {Protocol Ledger: Reconciled ClinicalTrials.gov v2 Phase II/III Studies and FDA Drugs@FDA Reference}, year = {2026}, howpublished = {\url{https://trials.meruai.co/}}, note = {Publication 47c4426df7e9d67d5bfe; primary federal sources: NIH NLM ClinicalTrials.gov REST API v2 (2018-2026) and U.S. FDA Drugs@FDA} } ``` ## 7. Ecosystem & Custom Healthcare Data Engineering - Healthcare Price & Patent Cliff Crosswalk: https://meruai.co/guides/healthcare-price-and-patent-cliff-crosswalk - Custom Healthcare Data Pipelines & Identifier Crosswalks: https://meruai.co/partnership?from=trials.meruai.co&utm_source=trials&utm_medium=ecosystem_bridge&utm_campaign=public_ledger